Boehringer Ingelheim gets the dirt flying on $42.5M R&D facility

Several top execs from Germany's Boehringer Ingelheim turned out at the company's U.S. headquarters in Connecticut to rub shoulders with the governor and other local officials as they touted plans for a $42.5 million research facility. Described as a safety assessment center, Boehringer is adding 63,000 square feet of space to support its R&D work in the area--a welcome development for a state that had been rattled by Pfizer's plans to slash its work in Groton.

"The fact that Boehringer Ingelheim continues to invest in its campus and create jobs is great news for Connecticut," said Governor Dannel P. Malloy, in a story by the Ridgefield Press. "This new facility expands the company's research and development capacities, and reaffirms its reputation as an innovative and forward-looking company. Boehringer Ingelheim is a valued member of the Connecticut business community and a key partner in our collective efforts to strengthen the state's bioscience industry."

Boehringer, not to be left behind in making bold pronouncements, boasted that the facility will combine "state-of-the-art technology, compliance with current good manufacturing practice and process flexibility to handle production of the many different types of APIs discovered in research," according to news reports.

- here's the story from the Ridgefield Press

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.